Update shared on05 Sep 2025
Fair value Decreased 1.99%Analysts maintain a positive long-term outlook on Zealand Pharma despite near-term competitive and pipeline risks, leading to a modest consensus price target reduction from DKK835.47 to DKK818.80 as updated risk assessments are incorporated.
Analyst Commentary
- Bullish analysts cite attractive entry points at current share levels, suggesting the stock is undervalued given long-term growth potential.
- Confidence maintained in Zealand Pharma's strategic story and prospects for upside, despite near-term pressure from competitors and concerns about amylin product setbacks.
- Target price reductions reflect updated risk assessments, particularly around increased competition and uncertainties in the amylin development pipeline.
- Continued Buy/Overweight ratings indicate positive long-term outlooks, with analysts expecting eventual recovery and performance enhancement.
- Adjusted targets incorporate both recent negative market developments and a belief in the company's core strengths and future catalysts.
What's in the News
- Zealand Pharma A/S removed from OMX Nordic 40 Index.
- Positive topline results from Phase 1b MAD trial of dapiglutide showed 11.6% mean body weight reduction after 28 weeks versus 0.2% for placebo, with no lifestyle changes.
- Dapiglutide was assessed as safe and well-tolerated at higher doses, with most adverse events mild and consistent with other incretin therapies; two participant withdrawals due to TEAEs.
Valuation Changes
Summary of Valuation Changes for Zealand Pharma
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from DKK835.47 to DKK818.80.
- The Future P/E for Zealand Pharma has fallen slightly from 95.60x to 93.32x.
- The Net Profit Margin for Zealand Pharma remained effectively unchanged, moving only marginally from 30.09% to 30.21%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.